Stock Upgrades and Downgrades Today

 StocksRunner
 
  StocksRunner
 
Follow  Message
 
 
 
Find out what happening right now and get all the pieces of the puzzle on important data activity before the major news sources break the story and see what are the trends
 

•  12 Feb 2025
 

AGNC Investment Corp ($AGNC) has crossed above its average 12-month target price of $10.17, now trading at $10.18. This signals that analysts who set that target may reassess their projections, potentially leading to adjustments in ratings or estimates.

Columbus McKinnon ($CMCO) faces a potential downgrade, with Moody’s placing the company's ratings under review. Investors should closely monitor any credit rating changes as they could impact borrowing costs and market sentiment.

CRISPR Therapeutics ($CRSP) received an upgrade from TD Cowen, moving to a "Hold" rating. While this isn’t an outright bullish call, it suggests the firm sees limited downside risk at current levels.

DoorDash ($DASH) is riding strong Q4 momentum, prompting seven analysts to raise their forecasts. Notably, Needham reaffirmed a Buy rating and increased its price target from $180 to $225, while Piper Sandler maintained its bullish stance. The company’s international growth initiatives appear to be a driving force behind these positive revisions.

Graco Inc. ($GGG) continues to show strong potential despite challenges in its industrial segment. The company benefits from product innovation, but investors should weigh these positives against macroeconomic headwinds affecting industrial demand.

Harmony Biosciences ($HRMY) saw Deutsche Bank initiate coverage with a Buy recommendation, signaling confidence in the company’s long-term prospects. Initiations often attract investor attention, particularly when issued by influential firms.

Humana ($HUM) faced a tough Q4 earnings season, leading to a rating downgrade. Analysts cite ongoing industry pressures and company-specific challenges as reasons for the revised outlook.

Mercury General ($MCY) received an upgrade from Raymond James, driven by strong results and potential for improved subrogation recoveries. This move suggests analysts see upside in the stock’s fundamentals.

Nvidia ($NVDA) remains a hot topic ahead of its earnings report on February 26. Evercore ISI continues to rate the stock as a strong buy, forecasting a 42% upside. Analysts remain confident despite concerns about demand cycles and AI growth.

NXP Semiconductors ($NXPI) earned an upgrade from Morgan Stanley, with analysts predicting 22% upside potential. This reflects optimism around the company's market position and upcoming catalysts.

PPG Industries ($PPG) saw a downgrade, with analysts turning less bullish on the stock. The reasons behind this shift remain unclear, but downgrades often indicate concerns about valuation, earnings potential, or industry trends.

Ralph Lauren ($RL) is now under new coverage with a mixed outlook. Analysts are assessing the company’s positioning and potential catalysts, though the sentiment appears cautious.

T-Mobile ($TMUS) crossed above its average analyst target of $256.74, now trading at $258.70. Stocks surpassing target prices often prompt analysts to reassess their ratings, potentially leading to upgrades or valuation adjustments.

Vertex Pharmaceuticals ($VRTX) received an upgrade from Canaccord Genuity following its Q4 results. The firm’s earnings performance likely played a role in this positive revision.

Wendy’s ($WEN) is gearing up for its Q4 earnings, with analysts looking at potential tailwinds from strong same-restaurant sales, technology investments, and international expansion. The upcoming report will provide further insight into these growth drivers.